Perspectives for Clinical Practice: The Latest Advances for HER2-positive Metastatic Breast Cancer

Perspectives for Clinical Practice: The Latest Advances for HER2-positive Metastatic Breast Cancer

Perspectives for Clinical Practice: The Latest Advances for HER2-positive Metastatic Breast Cancer

Discover the latest challenges and emerging opportunities in the treatment of HER2-positive metastatic breast cancer

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This activity will enhance knowledge and competence in the management of HER2-positive breast cancer. Dr. William Gradishar and Dr. Peter Schmid engage in a lively discussion regarding the latest clinical data supporting novel investigational and approved therapies for the treatment of HER2-positive metastatic breast cancer. They also review strategies to manage adverse events associated with these therapies.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    William J. Gradishar MD, FASCO, FACP
    Chief, Division of Hematology/Oncology
    Northwestern Memorial Hospital
    Chicago, IL 

    Dr. Gradishar has nothing to disclose. 

    Peter Schmid, FRCP, MD, PhD
    Chair of Cancer Medicine, Bart’s Cancer Institute  
    Queen Mary University of London
    London, England 

    Consulting Fees: AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma, Roche
    Contracted Research: Genentech, Novartis, Oncogenex, Roche
    Other - Consultancy (Spouse): Genentech, Roche

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo, MS has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the latest clinical data supporting novel investigational and approved therapies for the treatment of HER2-positive metastatic breast cancer
    • Devise strategies to manage adverse events (e.g., cardiotoxicity and pulmonary toxicity) associated with investigational and approved HER2-directed therapies
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pathologists, nurse practitioners, physician assistants, and nurses who manage patients with breast cancer.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from AstraZeneca and Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free